CN104822703A - Igf1r和pi3k的抑制剂的组合疗法 - Google Patents

Igf1r和pi3k的抑制剂的组合疗法 Download PDF

Info

Publication number
CN104822703A
CN104822703A CN201380038110.0A CN201380038110A CN104822703A CN 104822703 A CN104822703 A CN 104822703A CN 201380038110 A CN201380038110 A CN 201380038110A CN 104822703 A CN104822703 A CN 104822703A
Authority
CN
China
Prior art keywords
cancer
antibody
compound
igf1r
inhibitor
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201380038110.0A
Other languages
English (en)
Chinese (zh)
Inventor
X·黄
M·彼得斯
K·M·舒马赫
Z·A·曹
J·L·冈瑟特
D·D·E·常
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Novartis AG
Amgen Inc
Original Assignee
Novartis AG
Amgen Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis AG, Amgen Inc filed Critical Novartis AG
Publication of CN104822703A publication Critical patent/CN104822703A/zh
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Endocrinology (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Reproductive Health (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
CN201380038110.0A 2012-07-20 2013-07-19 Igf1r和pi3k的抑制剂的组合疗法 Pending CN104822703A (zh)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201261673809P 2012-07-20 2012-07-20
US61/673,809 2012-07-20
US201361759490P 2013-02-01 2013-02-01
US61/759,490 2013-02-01
PCT/US2013/051345 WO2014015280A1 (en) 2012-07-20 2013-07-19 Combination therapy of inhibitors for igf1 r and pi3k

Publications (1)

Publication Number Publication Date
CN104822703A true CN104822703A (zh) 2015-08-05

Family

ID=48875809

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201380038110.0A Pending CN104822703A (zh) 2012-07-20 2013-07-19 Igf1r和pi3k的抑制剂的组合疗法

Country Status (11)

Country Link
US (1) US8980259B2 (enExample)
EP (1) EP2875050A1 (enExample)
JP (1) JP2015524414A (enExample)
KR (1) KR20150041783A (enExample)
CN (1) CN104822703A (enExample)
AU (1) AU2013292298A1 (enExample)
BR (1) BR112015001212A2 (enExample)
CA (1) CA2879219A1 (enExample)
MX (1) MX2015000746A (enExample)
RU (1) RU2015105786A (enExample)
WO (1) WO2014015280A1 (enExample)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN107573416A (zh) * 2016-06-30 2018-01-12 中国科学院深圳先进技术研究院 抗igf1r和cd3特异性双靶向抗体、含该双靶向抗体表达盒的微环dna及应用
CN113512116A (zh) * 2020-04-10 2021-10-19 苏州普乐康医药科技有限公司 一种抗igf-1r抗体及其应用
WO2025016082A1 (zh) * 2023-07-18 2025-01-23 江苏桐孚高新材料有限公司 2-全氟烷基-4h-吡喃-4-酮衍生物的改进合成方法

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2865993A1 (en) * 2012-03-30 2013-10-03 Novartis Ag Compounds for use in the treatment of neuroblastoma, ewing's sarcoma or rhabdomyosarcoma
CA2937504A1 (en) * 2014-02-11 2015-08-20 Novartis Ag Pharmaceutical combinations comprising a pi3k inhibitor for the treatment of cancer
CN112494653A (zh) * 2015-02-05 2021-03-16 特尔诺沃有限公司 用于治疗癌症的irs/stat3双重调节剂与抗癌剂的组合
WO2016182988A1 (en) 2015-05-08 2016-11-17 Memorial Sloan Kettering Cancer Center Compositions and methods for treatment of glioma
TW201825465A (zh) 2016-09-23 2018-07-16 美商基利科學股份有限公司 磷脂醯肌醇3-激酶抑制劑
TW201815787A (zh) 2016-09-23 2018-05-01 美商基利科學股份有限公司 磷脂醯肌醇3-激酶抑制劑
TW201813963A (zh) 2016-09-23 2018-04-16 美商基利科學股份有限公司 磷脂醯肌醇3-激酶抑制劑

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006069202A2 (en) * 2004-12-22 2006-06-29 Amgen Inc. Compositions comprising anti-igf-i receptor antibodies and methods for obtaining said antibodies
US20100209420A1 (en) * 2007-04-10 2010-08-19 Exelixis, Inc. Methods of treating cancer using pyridopyrimidinone inhibitors of p13k alpha
WO2012016970A1 (en) * 2010-08-02 2012-02-09 Novartis Ag A crystalline form of (s)-pyrrolidine-1,2-dicarboxylic acid 2-amide 1-(4 -methyl-5-[2-(2,2,2-trifluoro-1,1-dimethyl-ethyl)-pyridin-4-yl]-thiazol-2-yl)-amide and its use as pi3k inhibitor

Family Cites Families (47)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5595756A (en) * 1993-12-22 1997-01-21 Inex Pharmaceuticals Corporation Liposomal compositions for enhanced retention of bioactive agents
FR2714383B1 (fr) 1993-12-29 1996-02-09 Centre Nat Rech Scient Contrôle de l'expression de gènes.
US7020563B1 (en) 1997-11-27 2006-03-28 Commonwealth Scientific And Industrial Research Organisation Method of designing agonists and antagonists to IGF receptor
US7173005B2 (en) 1998-09-02 2007-02-06 Antyra Inc. Insulin and IGF-1 receptor agonists and antagonists
US20030236190A1 (en) 1998-09-02 2003-12-25 Renuka Pillutla Isulin and IGF-1 receptor agonists and antagonists
US6875741B2 (en) 1998-09-02 2005-04-05 Renuka Pillutla Insulin and IGF-1 receptor agonists and antagonists
EP1006184A1 (en) 1998-12-03 2000-06-07 F. Hoffmann-La Roche Ag IGF-1 receptor interacting proteins (IIPs) genes coding therefor and uses thereof
US6608108B2 (en) 1999-10-15 2003-08-19 Johns Hopkins University Method for treatment of tumors using nordihydroguaiaretic acid derivatives
MA26040A1 (fr) 2001-01-05 2004-04-01 Pfizer Des anticorps pour recepteur i de facteur de croissance insulinique
CA2439735A1 (en) 2001-03-14 2002-09-19 Genentech, Inc. Igf antagonist peptides
SE0104140D0 (sv) 2001-12-07 2001-12-07 Astrazeneca Ab Novel Compounds
US7241444B2 (en) 2002-01-18 2007-07-10 Pierre Fabre Medicament Anti-IGF-IR antibodies and uses thereof
EP1798242B1 (fr) 2002-01-18 2013-01-23 Pierre Fabre Medicament Anticorps anti-IGF-IR et leurs applications
AU2003207708A1 (en) 2002-02-20 2003-09-09 Sirna Therapeutics, Inc. Rna interference mediated inhibition of map kinase genes
EP2316921B1 (en) 2002-05-24 2014-05-14 Merck Sharp & Dohme Corp. Neutralizing human anti-IGFR antibody
US8034904B2 (en) 2002-06-14 2011-10-11 Immunogen Inc. Anti-IGF-I receptor antibody
US7538195B2 (en) 2002-06-14 2009-05-26 Immunogen Inc. Anti-IGF-I receptor antibody
US7803781B2 (en) 2003-02-28 2010-09-28 Isis Pharmaceuticals, Inc. Modulation of growth hormone receptor expression and insulin-like growth factor expression
CA2518980A1 (en) 2003-03-14 2004-09-30 Pharmacia Corporation Antibodies to igf-i receptor for the treatment of cancers
US7378503B2 (en) 2003-04-02 2008-05-27 Hoffmann-La Roche Inc. Antibodies against insulin-like growth factor 1 receptor and uses thereof
JP2007535895A (ja) 2003-05-01 2007-12-13 イムクローン システムズ インコーポレイティド ヒトインシュリン様成長因子−１受容体に対する完全ヒト抗体
AR046071A1 (es) 2003-07-10 2005-11-23 Hoffmann La Roche Anticuerpos contra el receptor i del factor de crecimiento de tipo insulinico y los usos de los mismos
US7459554B2 (en) 2003-10-15 2008-12-02 Osi Pharmaceuticals, Inc. Imidazopyrazine tyrosine kinase inhibitors
PE20050928A1 (es) 2003-11-21 2005-11-08 Schering Corp Combinaciones terapeuticas de anticuerpo anti-igfr1
WO2005058967A2 (en) 2003-12-16 2005-06-30 Pierre Fabre Medicament Novel anti-insulin/igf-i hybrid receptor or anti-insulin/igf-i hybrid receptor and igf-ir antibodies and uses thereof
ES2368741T3 (es) 2004-02-25 2011-11-21 Dana-Farber Cancer Institute, Inc. Inhibidores del receptor 1 del factor de crecimiento de tipo insulina para inhibir el crecimiento de células tumorales.
SI1732898T1 (sl) 2004-03-12 2008-06-30 Analytecon Sa Tetrahidroizokinolinski in tetrahidrobenzazepinski derivati kot inhibitorji IGF-1R
ES2652440T3 (es) 2004-04-02 2018-02-02 OSI Pharmaceuticals, LLC Inhibidores de proteína cinasa heterobicíclicos sustituidos con anillo 6,6-bicíclico
US20090053239A1 (en) 2004-06-21 2009-02-26 Exelixis, Inc. ACACS As Modifiers of the IGF Pathway and Methods of Use
TW200613306A (en) 2004-07-20 2006-05-01 Osi Pharm Inc Imidazotriazines as protein kinase inhibitors
FR2873699B1 (fr) 2004-07-29 2009-08-21 Pierre Fabre Medicament Sa Nouveaux anticorps anti igf ir rt leurs utilisations
WO2006017443A2 (en) 2004-08-02 2006-02-16 Osi Pharmaceuticals, Inc. Aryl-amino substituted pyrrolopyrimidine multi-kinase inhibiting compounds
GB0426154D0 (en) 2004-11-29 2004-12-29 European Molecular Biology Lab Embl IGF-1 novel peptides
US8211929B2 (en) 2004-12-30 2012-07-03 Exelixis, Inc. Pyrimidine derivatives as kinase modulators and method of use
EP1885855A4 (en) 2005-05-05 2009-03-04 Valorisation Hsj Soc En Comman CYTOKIN RECEPTOR MODULATORS AND USES THEREOF
CN101612399B (zh) 2005-06-17 2013-11-27 英克隆有限责任公司 用作治疗继发性骨肿瘤的抗PDGFRα抗体
WO2007000328A1 (en) 2005-06-27 2007-01-04 Istituto Di Ricerche Di Biologia Molecolare P Angeletti Spa Antibodies that bind to an epitope on insulin-like growth factor 1 receptor and uses thereof
FR2888850B1 (fr) 2005-07-22 2013-01-11 Pf Medicament Nouveaux anticorps anti-igf-ir et leurs applications
US8044067B2 (en) 2005-09-09 2011-10-25 Analytecon S.A. Isoquinolines as IGF-1R inhibitors
BRPI0616731A2 (pt) 2005-09-09 2016-08-23 Analytecon Sa derivados de isoquinolina como inibidores do igf-1r
JP2009508833A (ja) 2005-09-16 2009-03-05 アストラゼネカ アクチボラグ Ｉｇｆ−１ｒチロシンキナーゼ活性の阻害のためのピリミジン誘導体類
US7884078B2 (en) 2006-02-10 2011-02-08 Massachusetts Institute Of Technology CPG15 compounds as insulin receptor and insulin-like growth factor receptor agonists
JP5250432B2 (ja) 2006-03-03 2013-07-31 ネルビアーノ・メデイカル・サイエンシーズ・エツセ・エルレ・エルレ キナーゼ阻害剤として活性なビシクロピラゾール
WO2007099166A1 (en) 2006-03-03 2007-09-07 Nerviano Medical Sciences S.R.L. Pyrazolo-pyridine derivatives active as kinase inhibitors
BRPI0709843A2 (pt) 2006-03-28 2011-07-26 Biogen Idec Inc anticorpos de anti-igf-1r e usos dos mesmos
AR064464A1 (es) 2006-12-22 2009-04-01 Genentech Inc Anticuerpos anti - receptor del factor de crecimiento insulinico
UA104147C2 (uk) 2008-09-10 2014-01-10 Новартис Аг Похідна піролідиндикарбонової кислоти та її застосування у лікуванні проліферативних захворювань

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006069202A2 (en) * 2004-12-22 2006-06-29 Amgen Inc. Compositions comprising anti-igf-i receptor antibodies and methods for obtaining said antibodies
US20100209420A1 (en) * 2007-04-10 2010-08-19 Exelixis, Inc. Methods of treating cancer using pyridopyrimidinone inhibitors of p13k alpha
WO2012016970A1 (en) * 2010-08-02 2012-02-09 Novartis Ag A crystalline form of (s)-pyrrolidine-1,2-dicarboxylic acid 2-amide 1-(4 -methyl-5-[2-(2,2,2-trifluoro-1,1-dimethyl-ethyl)-pyridin-4-yl]-thiazol-2-yl)-amide and its use as pi3k inhibitor

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN107573416A (zh) * 2016-06-30 2018-01-12 中国科学院深圳先进技术研究院 抗igf1r和cd3特异性双靶向抗体、含该双靶向抗体表达盒的微环dna及应用
CN113512116A (zh) * 2020-04-10 2021-10-19 苏州普乐康医药科技有限公司 一种抗igf-1r抗体及其应用
WO2025016082A1 (zh) * 2023-07-18 2025-01-23 江苏桐孚高新材料有限公司 2-全氟烷基-4h-吡喃-4-酮衍生物的改进合成方法

Also Published As

Publication number Publication date
KR20150041783A (ko) 2015-04-17
WO2014015280A1 (en) 2014-01-23
MX2015000746A (es) 2015-09-10
RU2015105786A (ru) 2016-09-10
AU2013292298A1 (en) 2015-02-05
CA2879219A1 (en) 2014-01-23
US20140023661A1 (en) 2014-01-23
BR112015001212A2 (pt) 2017-08-01
EP2875050A1 (en) 2015-05-27
US8980259B2 (en) 2015-03-17
JP2015524414A (ja) 2015-08-24

Similar Documents

Publication Publication Date Title
US8980259B2 (en) Combination therapy
CN115315256A (zh) 用抗tigit拮抗剂抗体治疗癌症的方法
CN113613674B (zh) 治疗小细胞肺癌的联用药物组合物
EP2827901B1 (en) Combination therapy of a mek inhibitor and an igf1r inhibitor
US20240424092A1 (en) Methods for treatment of cancer with an anti-tigit antagonist antibody
JP2018518483A (ja) 抗ｏｘ４０抗体及びｐｄ−１軸結合アンタゴニストを使用して癌を治療する方法
JP2018521019A (ja) 抗ｏｘ４０抗体を使用して癌を治療する方法
CN118267469A (zh) 治疗驱动基因阳性肺癌的联用药物组合物
CN113939315B (zh) 治疗黑色素瘤的联用药物组合物
CN113840601A (zh) 使用双特异性抗EGFR/c-Met抗体和第三代EGFR酪氨酸激酶抑制剂的组合疗法
WO2020228657A1 (zh) 喹啉衍生物与抗体联合治疗软组织肉瘤
CN112915202A (zh) 喹啉衍生物与pd-1单抗的药物组合
CN113117072A (zh) 喹啉衍生物与pd-1单抗的药物组合
AU2021320130B2 (en) Treatment of CLL
CN114667159B (zh) 喹啉衍生物与pd-1单抗的药物组合
TW202342527A (zh) 鱗狀非小細胞肺癌之治療
CN119032107A (zh) 胃癌的治疗
CN120346313A (zh) 治疗肿瘤的药物组合
WO2023230554A1 (en) Combination of a braf inhibitor, an egfr inhibitor, and a pd-1 antagonist for the treatment of braf v600e-mutant, msi-h/dmmr colorectal cancer
CN117940452A (zh) 用于治疗癌症的方法和组合物
CN114432438A (zh) 喹啉衍生物与pd-1单抗的药物组合
HK40056589A (en) Dosing for treatment with anti-tigit and anti-cd20 or anti-cd38 antibodies

Legal Events

Date Code Title Description
PB01 Publication
EXSB Decision made by sipo to initiate substantive examination
SE01 Entry into force of request for substantive examination
WD01 Invention patent application deemed withdrawn after publication

Application publication date: 20150805

WD01 Invention patent application deemed withdrawn after publication